

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b> SomnoMed Limited (ASX: SOM)
<b>ABN</b> 35 003 255 221

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Andrew Price
<b>Date of appointment</b>	17 January 2025

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b> N/A
--

+ See chapter 19 for defined terms.

## Appendix 3X Initial Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of securities
	N/A

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Non-executive director engagement terms
<b>Nature of interest</b>	Conditional contractual right to be issued options
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	A total of 300,000 options to be issued conditional upon shareholder approval, pursuant to the terms of the engagement as a non-executive director, with a commencement date of 17 January 2025. These options will have a 4 year expiry from commencement date and a \$0.69 exercise price. The options will vest on the first anniversary of the Grant Date.

---

+ See chapter 19 for defined terms.